# Astonea Labs (NSE: ASTONEALAB) share price, financials and shareholding

Source: https://app.pivotnow.in/stock/ASTONEALAB · Pivot · prices to 19 Oct 2026

With a market capitalisation of ₹281 Cr, it ranks 2097th by market cap among the 4,183 NSE companies Pivot tracks (a small-cap company by SEBI's rank bands). It belongs to the Pharma & Healthcare sector; its industry is Drug Manufacturers - Specialty & Generic.

Its return on equity was 29.1% in FY25. In Q3 FY25, the quarter ended 31 Dec 2024, revenue was ₹22 Cr and net profit ₹2 Cr, on a standalone basis. Promoters held 72.30% of the company as of 31 Mar 2026.

## Key numbers

| Metric | Value |
| --- | --- |
| Market cap | ₹281 Cr |
| ROE | 29.1% (FY25) |
| ROCE | 26.5% (FY25) |
| Debt to equity | 2.9 |

## Quarterly results (₹ crore, standalone)

| Quarter | Revenue | Revenue YoY | Net profit | Net profit YoY | EPS (₹) |
| --- | --- | --- | --- | --- | --- |
| Q3 FY25 | ₹22 Cr | — | ₹2 Cr | — | ₹2.55 |

## Annual results (₹ crore)

| Fiscal year | Revenue | Net profit |
| --- | --- | --- |
| FY25 | ₹98 Cr | ₹5 Cr |
| FY24 | ₹80 Cr | ₹4 Cr |
| FY23 | ₹67 Cr | ₹1 Cr |
| FY22 | ₹30 Cr | ₹0 Cr |

## Shareholding (31 Mar 2026)

- Promoters: 72.30%
- Foreign institutions: 0.00%
- Domestic institutions: 0.07%
- Non-institutions: 27.63%

## Peers

| Company | Price | Market cap | P/E | ROE |
| --- | --- | --- | --- | --- |
| [Ambalal Sarabhai Enterprises](https://app.pivotnow.in/stock/AMBALALSA) | ₹38.95 | ₹298 Cr | 16.8 | — |
| [Bijoy Hans](https://app.pivotnow.in/stock/BIJHANS) | — | ₹292 Cr | — | — |
| [Espire Hospital](https://app.pivotnow.in/stock/ESPIRE) | — | ₹274 Cr | — | — |
| [Zenotech Labs](https://app.pivotnow.in/stock/ZENOTECH) | — | ₹270 Cr | — | — |
| [Everest Organic](https://app.pivotnow.in/stock/EVERESTO) | — | ₹262 Cr | — | — |
| [Nath Bio-Genes (India)](https://app.pivotnow.in/stock/NATHBIOGEN) | ₹135.01 | ₹257 Cr | 6.4 | — |

## Questions and answers

### What is the market cap of Astonea Labs?

Astonea Labs' market capitalisation is ₹281 Cr (₹281 Cr) at the 19 Oct 2026 close, ranking 2097th among the NSE companies Pivot tracks.

### What is the ROE and ROCE of Astonea Labs?

Return on equity was 29.1% in FY25 and return on capital employed was 26.5% in FY25 (standalone figures).

### Is Astonea Labs a debt-free company?

No. Astonea Labs' debt-to-equity ratio was 2.9 in FY25, with total debt of ₹22 Cr.

### What were Astonea Labs' latest quarterly results?

For Q3 FY25 (quarter ended 31 Dec 2024), Astonea Labs reported revenue of ₹22 Cr and net profit of ₹2 Cr.

### What is the shareholding pattern of Astonea Labs?

As of 31 Mar 2026: promoters 72.30%, foreign institutions 0.00%, domestic institutions 0.07%, non-institutions 27.63%.

### Who are Astonea Labs' competitors?

The listed Pharma & Healthcare companies closest to Astonea Labs by market cap are Ambalal Sarabhai Enterprises, Bijoy Hans, Espire Hospital, Zenotech Labs, Everest Organic and Nath Bio-Genes (India).

### Is Astonea Labs a good stock to buy?

Pivot does not give buy or sell recommendations. This page sets out Astonea Labs' price history, valuation, profitability, quarterly results and ownership so you can judge it yourself, and Pivot's chart lets you test a strategy on ASTONEALAB against its own history before risking money. This is analysis, not financial advice.

---

Sources: NSE end-of-day bars (Pivot's market data store); Company filings via Moneycontrol; Exchange shareholding-pattern filings. This is analysis, not financial advice. Pivot is not a broker or a SEBI-registered investment adviser.